Encompass Health Corporation reported fourth‑quarter 2025 results that surpassed consensus expectations, with net operating revenue of $1.544 billion, up 9.9% year‑over‑year, and adjusted earnings per share of $1.46, a 24.8% increase from the same period last year. Adjusted EBITDA rose 15.9% to $335.6 million, reflecting a 15.9% year‑over‑year gain that outpaced revenue growth and signals expanding operating leverage. The company added 517 inpatient rehabilitation beds during the year, including eight new hospitals and 127 beds at existing facilities, reinforcing its capacity expansion strategy.
Revenue growth was driven by a 3.2% increase in same‑store discharges and a 4.1% rise in net patient revenue per discharge, underscoring sustained demand for intensive rehabilitation services amid an aging U.S. population and a persistent supply‑demand gap in the IRF market. The addition of new beds and hospitals not only supports current revenue but also positions Encompass to capture market share from lower‑acuity competitors, a strategy that has been a key focus of its prefabricated construction and joint‑venture initiatives.
Margin expansion is evident in the 15.9% jump in adjusted EBITDA, which exceeds the 9.9% revenue growth. The company attributes this to the amortization of capital costs and improved labor efficiencies, which together enhance operating leverage. Compared with Q4 2024, when revenue was $1.405 billion and adjusted EPS was $1.17, the year‑over‑year gains demonstrate accelerating performance and a strengthening cost structure.
Management raised 2026 guidance, projecting revenue of $6.365 billion to $6.465 billion and adjusted EBITDA of $1.340 billion to $1.380 billion—an upward revision that reflects confidence in continued demand and margin improvement. The guidance increase signals that Encompass expects to sustain its capacity expansion momentum and benefit from the ongoing supply‑demand imbalance in the IRF market. CEO Mark Tarr emphasized that the company’s “stellar 2025” performance and the addition of new beds position it well to meet the growing needs of an aging population.
The earnings beat and guidance lift spurred a strong market reaction, with the stock rising 17.5% to 20.53% in after‑hours trading. Analysts highlighted the EPS beat of $0.17 over the consensus estimate of $1.29 and the revenue beat of $0.004 billion over the $1.54 billion estimate as key drivers of the positive response.
Encompass Health’s Q4 results and forward outlook reinforce its competitive moat in the inpatient rehabilitation sector, demonstrating robust demand, effective cost management, and a clear path to continued growth. The company’s focus on capacity expansion and operational efficiency positions it to capitalize on demographic tailwinds while maintaining margin expansion in a market that remains constrained by supply.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.